Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC 2026
ACORAMIDIS
Acoramidis reduces days lost to death and/or cardiovascular-related hospitalization, preserving time alive outside the hospital in participants with ATTR-CM: results from ATTRibute-CM
Date/Time:
August 30, 2026 | 8:15 AM – 9:00 AM
Session:
Real-world cardiovascular care: health economics, resource use, and long-term outcomes
Type:
Moderated ePoster
Presenting Author:
Richard Wright
Acoramidis improves health-related quality of life in wild-type and variant transthyretin amyloid cardiomyopathy: An EQ-5D-5L subgroup analysis from ATTRibute-CM
Date/Time:
August 30, 2026 | 8:15 AM – 9:00 AM
Session:
New insights into cardiac amyloidosis
Type:
Moderated ePoster
Presenting Author:
Emer Joyce
Improvement of health status with acoramidis in patients with wild-type and variant transthyretin amyloid cardiomyopathy: KCCQ domains analysis from the ATTRibute-CM study
Date/Time:
August 30, 2026 | 15:15 PM – 16:00 PM
Session:
New insights into cardiac amyloidosis
Type:
Moderated ePoster
Presenting Author:
Nitasha Sarswat
Long-term improvement in myocardial structure and function in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with acoramidis compared with a natural history cohort
Date/Time:
August 28, 2026 | 16:15 PM – 17:00
Session:
Cardiac magnetic resonance of amyloidosis and myocardial remodelling
Type:
Moderated ePoster
Presenting Author:
Awais Sheikh
A novel AI-derived digital biomarker for monitoring disease progression in ATTR-CM: first-in-trial use of a computer vision AI-ECG algorithm within a phase 3 pivotal randomized controlled trial
Date/Time:
August 31, 2026 | 11:15 AM – 12:00 PM
Session:
Artificial intelligence and big data for cardiovascular care
Type:
Moderated ePoster
Presenting Author:
Rohan Khera
FINERENONE
Systolic blood pressure variability and effect of finerenone treatment in patients with chronic kidney disease and type 2 diabetes: a FIDELITY analysis
Date/Time:
August 29, 2026 | 8:35 – 8:45
Session:
Secondary prevention after myocardial infarction Type: Oral Presentation
Type:
Oral Presentation
Presenting Author:
Sanjay Rajagopalan
Real-world effectiveness and safety of finerenone in patients with chronic kidney disease and type 2 diabetes in the United States: A FOUNTAIN platform analysis
Date/Time:
August 29, 2026 | 16:35 – 16:45
Session:
Cardiovascular pharmacotherapy in advanced kidney disease: efficacy, safety, and outcomes
Type:
Oral Presentation
Presenting Author:
Sapna Rao
Efficacy and safety of finerenone in patients with chronic kidney disease and cardiovascular diseases: An individual participant data pooled analysis (INFINITY)
Date/Time:
August 30, 2026 | 14:45 – 15:00
Session:
Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition
Type:
Oral Presentation
Presenting Author:
Carolyn SP Lam
VERICIGUAT
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
